Avidity Biosciences, Inc. – NASDAQ:RNA
Founder-led company
Avidity Biosciences stock price today
$44.12
+14.00
+46.53%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 6 hours
Avidity Biosciences stock price monthly change
-32.79%
month
Avidity Biosciences stock price quarterly change
-32.79%
quarter
Avidity Biosciences stock price yearly change
+221.69%
year
Avidity Biosciences key metrics
Market Cap | 3.70B |
Enterprise value | 475.87M |
P/E | -4.23 |
EV/Sales | 51.59 |
EV/EBITDA | -2.78 |
Price/Sales | 87.33 |
Price/Book | 1.39 |
PEG ratio | 0.08 |
EPS | -2.95 |
Revenue | 10.87M |
EBITDA | -252.83M |
Income | -228.68M |
Revenue Q/Q | 58.66% |
Revenue Y/Y | 12.50% |
Profit margin | -1886.33% |
Oper. margin | -1939.65% |
Gross margin | 56.93% |
EBIT margin | -1939.65% |
EBITDA margin | -2326.02% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAvidity Biosciences stock price history
Avidity Biosciences stock forecast
Avidity Biosciences financial statements
| Jun 2023 | 2.31M | -47.02M | -2030.44% |
|---|---|---|---|
| Sep 2023 | 2.81M | -52.35M | -1857.98% |
| Dec 2023 | 2.19M | -60.44M | -2756.18% |
| Mar 2024 | 3.54M | -68.85M | -1943.41% |
| Sep 2025 | 3.70M | -69.96M | -1887.27% |
|---|---|---|---|
| Oct 2025 | 6M | -80.52M | -1342.09% |
| Dec 2025 | 6M | -80.52M | -1342.09% |
| Mar 2026 | 6.45M | -97.66M | -1512.81% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 0.01% |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 610784000 | 51.60M | 8.45% |
|---|---|---|---|
| Sep 2023 | 573163000 | 55.69M | 9.72% |
| Dec 2023 | 628555000 | 127.79M | 20.33% |
| Mar 2024 | 951474000 | 120.57M | 12.67% |
| Jun 2023 | -49.80M | 46.04M | 38.97M |
|---|---|---|---|
| Sep 2023 | -36.79M | -31.47M | 40K |
| Dec 2023 | 16.50M | 51.04M | 31.89M |
| Mar 2024 | -70.38M | -32.74M | 389.44M |
Avidity Biosciences alternative data
| Aug 2023 | 186 |
|---|---|
| Sep 2023 | 186 |
| Oct 2023 | 186 |
| Nov 2023 | 186 |
| Dec 2023 | 186 |
| Jan 2024 | 186 |
| Feb 2024 | 186 |
| Mar 2024 | 253 |
| Apr 2024 | 253 |
| May 2024 | 253 |
| Jun 2024 | 253 |
| Jul 2024 | 253 |
Avidity Biosciences other data
67.05%
-32.95%
of RNA is owned by hedge funds
80
-66
34.97M
-36.63M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 14761 |
| Mar 2024 | 0 | 268641 |
| Apr 2024 | 0 | 53000 |
| May 2024 | 0 | 108000 |
| Jun 2024 | 0 | 356272 |
| Jul 2024 | 0 | 33000 |
| Aug 2024 | 0 | 33000 |
| Sep 2024 | 0 | 223937 |
| Oct 2024 | 0 | 122500 |
| Nov 2024 | 0 | 69460 |
| Dec 2024 | 0 | 115899 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | FLANAGAN W. MICHAEL officer: CSTO | Common Stock | 12,742 | $32.66 | $416,154 | ||
Sale | MACLEAN MICHAEL F officer: Chief Fi.. | Common Stock | 11,151 | $32.66 | $364,192 | ||
Sale | BOYCE SARAH director, officer.. | Common Stock | 31,855 | $32.66 | $1,040,384 | ||
Sale | MCCARTHY TERESA officer: Chief Human Resources .. | Common Stock | 11,151 | $32.66 | $364,192 | ||
Option | MCCARTHY TERESA officer: Chief Human Resources .. | Common Stock | 25,000 | $14.22 | $355,500 | ||
Sale | MCCARTHY TERESA officer: Chief Human Resources .. | Common Stock | 25,000 | $33.26 | $831,600 | ||
Option | MCCARTHY TERESA officer: Chief Human Resources .. | Stock Option (Right to Buy) | 25,000 | $14.22 | $355,500 | ||
Option | FLANAGAN W. MICHAEL officer: CSTO | Common Stock | 24,000 | $22.47 | $539,280 | ||
Option | FLANAGAN W. MICHAEL officer: CSTO | Stock Option (Right to Buy) | 24,000 | $22.47 | $539,280 | ||
Sale | FLANAGAN W. MICHAEL officer: CSTO | Common Stock | 24,000 | $35.77 | $858,408 |
| Patent |
|---|
Grant Filling date: 26 Mar 2021 Issue date: 20 Sep 2022 |
Grant Filling date: 31 Aug 2021 Issue date: 2 Aug 2022 |
Application Filling date: 24 Apr 2020 Issue date: 28 Jul 2022 |
Grant Filling date: 30 Jun 2021 Issue date: 21 Jun 2022 |
Application Filling date: 17 Nov 2021 Issue date: 5 May 2022 |
Grant Filling date: 31 Aug 2021 Issue date: 26 Apr 2022 |
Application Filling date: 12 Oct 2021 Issue date: 31 Mar 2022 |
Application Filling date: 31 Aug 2021 Issue date: 10 Mar 2022 |
Application Filling date: 17 Nov 2021 Issue date: 3 Mar 2022 |
Grant Filling date: 17 Sep 2020 Issue date: 22 Feb 2022 |
| Quarter | Transcript |
|---|---|
| Q3 2014 17 Nov 2014 | Q3 2014 Earnings Call Transcript |
| Q2 2014 12 Aug 2014 | Q2 2014 Earnings Call Transcript |
| Q1 2014 20 May 2014 | Q1 2014 Earnings Call Transcript |
| Q4 2013 19 Mar 2014 | Q4 2013 Earnings Call Transcript |
Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
Avidity Biosciences: Large Devaluation Of Stock Presents Opportunity
Avidity Biosciences: An Interesting Diversification
Avidity Biosciences: Positive 2023 Data Readouts Key To AOC Tech Advancement
Avidity Biosciences: Mixed Data Could Create An Opportunity
Avidity Biosciences: Helping Deliver Oligonucleotides Outside Liver Cells
Diving Into Dyne Therapeutics
Avidity Biosciences Will Rise As It Revolutionizes The Field Of RNA Therapeutics
Avidity Biosciences: Unique Antibody-Oligonucleotide Conjugate Technology
-
What's the price of Avidity Biosciences stock today?
One share of Avidity Biosciences stock can currently be purchased for approximately $44.12.
-
When is Avidity Biosciences's next earnings date?
Unfortunately, Avidity Biosciences's (RNA) next earnings date is currently unknown.
-
Does Avidity Biosciences pay dividends?
No, Avidity Biosciences does not pay dividends.
-
How much money does Avidity Biosciences make?
Avidity Biosciences has a market capitalization of 3.70B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3.64% to 9.56M US dollars.
-
What is Avidity Biosciences's stock symbol?
Avidity Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "RNA".
-
What is Avidity Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Avidity Biosciences?
Shares of Avidity Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Avidity Biosciences's key executives?
Avidity Biosciences's management team includes the following people:
- Ms. Sarah Boyce Pres, Chief Executive Officer & Director(age: 53, pay: $823,090)
- Mr. Michael F. MacLean Chief Financial Officer(age: 59, pay: $501,340)
- Dr. Troy Edward Wilson Co-Founder & Chairman(age: 56, pay: $132,000)
-
Is Avidity Biosciences founder-led company?
Yes, Avidity Biosciences is a company led by its founder Dr. Troy Edward Wilson.
-
How many employees does Avidity Biosciences have?
As Jul 2024, Avidity Biosciences employs 253 workers.
-
When Avidity Biosciences went public?
Avidity Biosciences, Inc. is publicly traded company for more then 5 years since IPO on 12 Jun 2020.
-
What is Avidity Biosciences's official website?
The official website for Avidity Biosciences is aviditybiosciences.com.
-
Where are Avidity Biosciences's headquarters?
Avidity Biosciences is headquartered at 10578 Science Center Drive, San Diego, CA.
-
How can i contact Avidity Biosciences?
Avidity Biosciences's mailing address is 10578 Science Center Drive, San Diego, CA and company can be reached via phone at 858 401 7900.
Avidity Biosciences company profile:
Avidity Biosciences, Inc.
aviditybiosciences.comExchange:
NASDAQ
Full time employees:
253
Industry:
Biotechnology
Sector:
Healthcare
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
10578 Science Center Drive
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001599901
ISIN: US05370A1088
CUSIP: 05370A108
